drugset / Trial / NCT05279131

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

NCT05279131

Phase 3 Completed 105 enrolled Almirall, S.A.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.

Timeline

Start
2022-06-28
Primary completion
2022-12-28
Completion
2022-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirbanibulin Small molecule 1 % Topical

Indications